183 related articles for article (PubMed ID: 19448373)
21. Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.
Sambrook PN; Kotowicz M; Nash P; Styles CB; Naganathan V; Henderson-Briffa KN; Eisman JA; Nicholson GC
J Bone Miner Res; 2003 May; 18(5):919-24. PubMed ID: 12733733
[TBL] [Abstract][Full Text] [Related]
22. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis.
Buckley L; Guyatt G; Fink HA; Cannon M; Grossman J; Hansen KE; Humphrey MB; Lane NE; Magrey M; Miller M; Morrison L; Rao M; Robinson AB; Saha S; Wolver S; Bannuru RR; Vaysbrot E; Osani M; Turgunbaev M; Miller AS; McAlindon T
Arthritis Rheumatol; 2017 Aug; 69(8):1521-1537. PubMed ID: 28585373
[TBL] [Abstract][Full Text] [Related]
23. Management of glucocorticoid-induced osteoporosis in male veterans.
Elliott ME; Farrah RM; Binkley NC; Carnes ML; Gudmundsson A
Ann Pharmacother; 2000 Dec; 34(12):1380-4. PubMed ID: 11144692
[TBL] [Abstract][Full Text] [Related]
24. Prevention and treatment of glucocorticoid-induced osteoporosis.
Curtis JR; Saag KG
Curr Osteoporos Rep; 2007 Mar; 5(1):14-21. PubMed ID: 17320023
[TBL] [Abstract][Full Text] [Related]
25. Primary and secondary prophylaxis to the use of inhaled glucocorticoid in primary health care.
Nielsen BR; Jørgensen NR; Schwarz P
J Asthma; 2008 Aug; 45(6):519-22. PubMed ID: 18612907
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of care delivery by a novel multidisciplinary bone health clinic for patients at risk of glucocorticoid-induced osteoporosis.
Abdullah H; Koller G; Zuna I; Yuksel N; Charrois T; Mandhane R; Cotton K; Danilak M; Bell H; Ye C
Arch Osteoporos; 2021 Jul; 16(1):108. PubMed ID: 34347188
[TBL] [Abstract][Full Text] [Related]
27. [Glucocorticoid induced osteoporosis].
Anić B; Mayer M
Reumatizam; 2014; 61(2):105-12. PubMed ID: 25427404
[TBL] [Abstract][Full Text] [Related]
28. Glucocorticoid induced osteoporosis.
Hu K; Adachi JD
Expert Rev Endocrinol Metab; 2019 Jul; 14(4):259-266. PubMed ID: 31094232
[TBL] [Abstract][Full Text] [Related]
29. Prophylactic calcium and vitamin D treatments in steroid-treated children with nephrotic syndrome.
Bak M; Serdaroglu E; Guclu R
Pediatr Nephrol; 2006 Mar; 21(3):350-4. PubMed ID: 16382319
[TBL] [Abstract][Full Text] [Related]
30. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
Mok CC; Ho LY; Ma KM
Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
[TBL] [Abstract][Full Text] [Related]
31. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Mok CC; Tong KH; To CH; Siu YP; Ma KM
Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of osteoporosis risk and initiation of a nurse practitioner intervention program in an orthopedic practice.
Seuffert P; Sagebien CA; McDonnell M; O'Hara DA
Arch Osteoporos; 2016; 11():10. PubMed ID: 26847628
[TBL] [Abstract][Full Text] [Related]
33. Glucocorticoid-induced osteoporosis: who to treat with what agent?
Rizzoli R; Biver E
Nat Rev Rheumatol; 2015 Feb; 11(2):98-109. PubMed ID: 25385412
[TBL] [Abstract][Full Text] [Related]
34. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
Arthritis Rheum; 2001 Jul; 44(7):1496-503. PubMed ID: 11465699
[TBL] [Abstract][Full Text] [Related]
35. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
36. Management of bone disease in patients on long term glucocorticoid therapy.
Compston JE
Gut; 1999 Jun; 44(6):770-2. PubMed ID: 10323872
[No Abstract] [Full Text] [Related]
37. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice.
Ledwich LJ; Clarke K
J Clin Rheumatol; 2009 Mar; 15(2):61-4. PubMed ID: 19265346
[TBL] [Abstract][Full Text] [Related]
38. Increase in prophylaxis of glucocorticoid-induced osteoporosis by pharmacist feedback: a randomised controlled trial.
Klop C; de Vries F; Vinks T; Kooij MJ; van Staa TP; Bijlsma JW; Egberts AC; Bouvy ML
Osteoporos Int; 2014 Jan; 25(1):385-92. PubMed ID: 24221450
[TBL] [Abstract][Full Text] [Related]
39. Fracture risk in systemic lupus erythematosus patients over 28 years.
Garelick D; Pinto SM; Farinha F; Pires T; Khan E; Isenberg D
Rheumatology (Oxford); 2021 Jun; 60(6):2765-2772. PubMed ID: 33221918
[TBL] [Abstract][Full Text] [Related]
40. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
